ARS Pharmaceuticals, Inc. SPRY Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s accrued expenses?
- ARS Pharmaceuticals, Inc. (SPRY) reported accrued expenses of $592K in Q1 2026.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s accrued expenses?
- Over 3 years (2020 to 2025), ARS Pharmaceuticals, Inc.'s accrued expenses has grown at a -51.9% compound annual growth rate (CAGR), from $5.28M to $588K.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.